Go Pro
NASDAQ:BMGL

Basel Medical Group Q2 2026 Earnings Report

Basel Medical Group logo
$4.92 -0.38 (-7.08%)
As of 10:37 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Basel Medical Group EPS Results

Actual EPS
$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Basel Medical Group Revenue Results

Actual Revenue
$3.21 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Basel Medical Group Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Basel Medical Group Earnings Headlines

This biotech’s early trial data shows 63% cancer reduction
Time-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer cells - and early human data revealed up to a 63.7 percent reduction in cancer burden. One NASDAQ-listed biotech's TriKE platform is designed to keep these immune cells locked onto tumors longer. Its next-generation version, showing potential for 10 to 40 times greater potency, has just cleared an important FDA milestone.tc pixel
See More Basel Medical Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Basel Medical Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Basel Medical Group and other key companies, straight to your email.

About Basel Medical Group

Basel Medical Group (NASDAQ:BMGL). is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement. The company was founded by Man Hing Yip on August 10, 2023 and is headquartered in Singapore.

View Basel Medical Group Profile